Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of Injectable Niagen Plus in Healthy Adults
NCT07251608Phase 1Recruiting
- Sponsor
- Niagen Bioscience
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Niagen Plus in fatigue (4 arms), sponsored by Niagen Bioscience. Primary endpoints: Incidence and severity of adverse events, Blood Pressure and 8 more. Started Oct 2025; status: recruiting.
02
Drugs
Niagen Plus
03
Conditions
fatigue
Beyond the preview
Go deeper on NCT07251608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251608.